Stavroula Petroulia

Stavroula Petroulia

Auto-generated profile, based on publicly available information

Stavroula Petroulia

Chemical Genomics Centre of the Max Planck Society Dortmund, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
KWKim Wendrich
Kim Wendrich
KGKai Gallant
Kai Gallant
SRSarah Recknagel
Sarah Recknagel
SPStavroula Petroulia
Stavroula Petroulia
NKNafizul Haque Kazi
Nafizul Haque Kazi
MGMalte Gersch
Malte Gersch
Ubiquitin-specific proteases (USPs) represent the largest class of human deubiquitinases (DUBs) and comprise its phylogenetically most distant members USP53 and USP54, which are annotated as catalytically inactive pseudoenzymes. Conspicuously, mutations within the USP domain of USP53 cause progressive familial intrahepatic cholestasis. Here, we report the discovery that USP53 and USP54 are active DUBs with high specificity for K63-linked polyubiquitin. We demonstrate how USP53 mutations abrogate catalytic activity, implicating loss of DUB activity in USP53-mediated pathology. Depletion of USP53 increases K63-linked ubiquitination of tricellular junction components. Assays with substrate-bound polyubiquitin reveal that USP54 cleaves within K63-linked chains, whereas USP53 can en bloc deubiquitinate substrate proteins in a K63-linkage-dependent manner. Biochemical and structural analyses uncover underlying K63-specific S2 ubiquitin-binding sites within their catalytic domains. Collectively, our work revises the annotation of USP53 and USP54, provides reagents and a mechanistic framework to investigate K63-linked polyubiquitin decoding and establishes K63-linkage-directed deubiquitination as a new DUB activity.

1 July 2025 in Cancer Research Communications
Verified
Journal Article
Open access
SPStavroula Petroulia
Stavroula Petroulia
KHKathryn Hockemeyer
Kathryn Hockemeyer
STShashank Tiwari
Shashank Tiwari
PBPietro Berico
Pietro Berico
SSSama Shamloo
Sama Shamloo
JIJochen Imig
Jochen Imig
Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma. Significance: LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.

9 July 2025
Verified
Other
Open access
SPStavroula Petroulia
Stavroula Petroulia
KHKathryn Hockemeyer
Kathryn Hockemeyer
STShashank Tiwari
Shashank Tiwari
PBPietro Berico
Pietro Berico
SSSama Shamloo
Sama Shamloo
JIJochen Imig
Jochen Imig
XLOC_030781 CRISPRi knockdown and RNA-seq transcriptomic expression analysis in 501mel-dCas9-KRAB. A, Principal component analysis (PCA) of sgXLOC_030781 CRISPRi at days 3 and 5 after infection vs. day 0 negative control (n = 2). B, Volcano plot of significantly differentially expressed genes (red) upon sgXLOC_030781 knockdown at day 3; P value cutoff = 0.05 and log2 fc = 1. C, GO enrichment analysis of up- and downregulated gene sets upon sgXLOC_030781 knockdown at day 3. D, GSEA enrichment analysis of each top example of upregulated (ER to Golgi vesicle transport, left) and downregulated genes (DNA replication–dependent nucleosome assembly, right). E, Upstream TF analysis of up- and downregulated genes using ChEA upon sgXLOC_030781 knockdown at day 3.

9 July 2025
Verified
Other
Open access
SPStavroula Petroulia
Stavroula Petroulia
KHKathryn Hockemeyer
Kathryn Hockemeyer
STShashank Tiwari
Shashank Tiwari
PBPietro Berico
Pietro Berico
SSSama Shamloo
Sama Shamloo
JIJochen Imig
Jochen Imig
Table S5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening

9 July 2025
Verified
Other
Open access
SPStavroula Petroulia
Stavroula Petroulia
KHKathryn Hockemeyer
Kathryn Hockemeyer
STShashank Tiwari
Shashank Tiwari
PBPietro Berico
Pietro Berico
SSSama Shamloo
Sama Shamloo
JIJochen Imig
Jochen Imig
Samples and expression values Badal et al and Kunz et al

9 July 2025
Verified
Other
Open access
SPStavroula Petroulia
Stavroula Petroulia
KHKathryn Hockemeyer
Kathryn Hockemeyer
STShashank Tiwari
Shashank Tiwari
PBPietro Berico
Pietro Berico
SSSama Shamloo
Sama Shamloo
JIJochen Imig
Jochen Imig
Results XLOC_030781 KD RNA-Seq